Pfizer
Corina O'Connell has a diverse work experience in various finance and investigative roles. Corina is currently working as the Global Investigator Payments Team Lead at Pfizer since June 2021. Prior to this, they held multiple roles at ICON plc, including Director of Investigator Payments from April 2018 to May 2021, Associate Director of Transparency Reporting from April 2015 to April 2018, Associate Director of Finance from April 2005 to June 2015, and Financial Analyst from April 2003 to March 2005. Corina also worked as a Management Accountant at Tyco Electronics from July 1998 to March 2003.
Corina O'Connell attended Dublin City University from 1994 to 1998, majoring in Accounting and Finance.
This person is not in any teams
This person is not in any offices
Pfizer
615 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.